Accuray Marks Significant Achievement for Cancer Patients in Melbourne, Australia with Initial SBRT Treatments Utilizing the CyberKnife® System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 08 2025
0mins
Source: Newsfilter
Partnership Announcement: 5D Clinics and Icon Group have launched a joint venture to operate CyberKnife System centers across Australia, starting with the first treatments in Melbourne, aimed at improving access to advanced cancer care.
Patient Impact: The CyberKnife S7™ System offers precise and efficient radiation therapy, significantly reducing treatment time and hospital stays, as highlighted by patient testimonials emphasizing the benefits of this innovative technology.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ARAY with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ARAY
Wall Street analysts forecast ARAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARAY is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.793
Low
4.00
Averages
4.00
High
4.00
Current: 0.793
Low
4.00
Averages
4.00
High
4.00
About ARAY
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Accuray (NASDAQ:ARAY) to Report Q2 FY2026 Financial Results on February 4, 2026
- Earnings Call Schedule: Accuray is set to hold a conference call on February 4, 2026, at 1:30 PM PT (4:30 PM ET) to report its Q2 FY2026 financial results, reflecting the company's commitment to transparency and investor communication.
- Dial-in Information: The call can be accessed via US number 1-833-316-0563 and international number 1-412-317-5747, indicating the company's effort to provide accessible participation channels for global investors, enhancing its appeal to international stakeholders.
- Replay Availability: A replay of the call will be available approximately one hour after its conclusion, with US number 1-855-669-9658 and international number 1-412-317-0088, conference ID 8587254, ensuring that investors who cannot attend live can still access critical information, thereby improving information accessibility.
- Webcast and Replay: The call will be live-streamed on the company's investor relations website and will remain available until the announcement of Q3 FY2026 results, showcasing Accuray's modernization in information dissemination and enhancing investor engagement.
Continue Reading
Accuray Initiates Strategic Transformation Plan Expected to Boost Annual Profit by $25 Million
- Strategic Transformation Initiated: Accuray has announced the first phase of its comprehensive strategic transformation plan aimed at enhancing accountability and cost control, with an expected annual profit increase of approximately $25 million, thereby strengthening the company's market competitiveness.
- Organizational Structure Optimization: The plan will streamline the commercial structure, centralize core functions, and elevate global service and product development heads to report directly to the CEO, reallocating resources to support sales growth.
- Layoffs and Outsourcing: The company anticipates a global headcount reduction of about 15%, with expected cost savings of approximately $12 million in fiscal 2026 achieved through layoffs and outsourcing non-core activities, further enhancing profitability.
- Restructuring Charges Expected: Accuray expects to incur around $11 million in restructuring charges during the second, third, and fourth quarters of fiscal 2026, primarily related to workforce reductions and facility consolidations, ensuring the smooth implementation of the transformation plan.
Continue Reading